# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Pierre Le Moyne d'Iberville (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET014-SYN
- Date: 2026-03-31
- Fictional facility: St. Posthumous Health Center
- Fictional author: Marguerite Delacroix-Boateng, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Six-week review after chloroquine and primaquine. **S**

## History of present illness

Mr. Le Moyne d'Iberville returns four weeks after starting treatment. He took all four doses of chloroquine, with mild nausea on the first day, and finished the 14 days of primaquine two weeks ago, taking it with food; he had mild stomach cramps for a few days and no dark urine, breathlessness or blue lips. He has had no fever. He did not have the smear and PCR that were meant for a week after the last primaquine dose, because the date was not booked. He explained the fever plan back correctly. **S**

| Element | Detail |
|---|---|
| Chloroquine | All doses taken; mild nausea on the first day |
| Primaquine | 14 days completed two weeks ago; mild stomach cramps |
| Fever | None |
| Missed test | Post-treatment smear and PCR not done |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or chills; energy better |
| Gastrointestinal | Negative | Cramps settled; no jaundice |
| Genitourinary | Negative | No dark urine |

3 systems reviewed. **S**

## Current medications

- No current medications. **S**

## Allergies

- No known allergy **S**

## Objective

BP 122/78 mmHg; pulse 66 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 69 kg; BMI 22.5 kg/m². All vital signs are synthetic.

Hemoglobin: 13.6 g/dL; Platelets: 212 10*3/uL; Total bilirubin: 0.7 mg/dL. All results are synthetic.

## Change since baseline

- Hemoglobin: 13 g/dL (low) at baseline, 13.6 g/dL at this visit **S**
- Platelets: 141 10*3/uL (low) at baseline, 212 10*3/uL at this visit **S**
- Total bilirubin: 1.1 mg/dL at baseline, 0.7 mg/dL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; temperature 36.6 C, blood pressure 122/78, pulse 66, weight 69.0 kg |
| Eyes | No pallor; sclerae white |
| Skin | No cyanosis |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Relapsing P. vivax malaria, radical cure completed** (B51.9). Course completed without hemolysis: hemoglobin 13.6 g/dL, platelets 212 x10^3/uL and bilirubin 0.7 mg/dL, all improved. The smear today is negative; the PCR is sent and will be reported by telephone. Radical cure is complete; relapse is now unlikely but possible, so surveillance continues. **S**
   - Keep the fever action plan, including during travel and after return.
   - No further malaria tests unless he has a fever.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count and bilirubin for hemolysis on primaquine | Baseline, then after the course | Completed today | Hemoglobin 13.6 g/dL, platelets 212 x10^3/uL, bilirubin 0.7 mg/dL: no hemolysis |
| Laboratory | Follow-up blood smear after treatment (ideally within one week of finishing) | About one week after finishing | Completed today | Smear negative today; PCR sent. Protocol deviation: the smear and PCR ordered for one week after the last primaquine dose were not drawn, because no date was booked; they were drawn today, two weeks after finishing. No harm resulted: the smear is negative and he has had no fever. Corrective action: book post-treatment tests with a date when treatment starts |
| Medication safety | Adverse effects: nausea, abdominal pain, dark urine, breathlessness, cyanosis | During the course | Completed today | Mild nausea on chloroquine and mild cramps on primaquine; no dark urine or cyanosis |
| Medication safety | Adherence to the full course | At the end of the course | Completed today | All doses of both medicines taken |
| Self-management | Relapse surveillance and the fever action plan | Every visit | Completed today | No fever; explained the plan back correctly |

## Goal progress

- No further malaria relapse in the six months after radical cure. In progress; target 2026-10-13. **S**
- All required and recommended travel vaccines given, with a valid yellow fever certificate, at least ten days before departure. In progress; target 2026-10-13. **S**
- Knows to have a malaria test the same day for any fever, during travel and for months after return. Outcome by 2026-03-31: Carries a fever card and explained the plan back correctly. **S**

## Guideline basis

- Treatment of Uncomplicated Malaria (clinical guidance) (2026), Centers for Disease Control and Prevention
- CDC Yellow Book: Health Information for International Travel, 2026 edition. Malaria (2026), Centers for Disease Control and Prevention

## Follow-up

- Preventive visit in three weeks. Pre-travel visit in the summer. **S**
- Next scheduled visit 2026-04-21: periodic adult preventive visit. **S**
